Annual accounts receivable:
$10.04B+$421.58M(+4.38%)Summary
- As of today (May 29, 2025), NVO annual accounts receivable is $10.04 billion, with the most recent change of +$421.58 million (+4.38%) on December 31, 2024.
- During the last 3 years, NVO annual accounts receivable has risen by +$3.85 billion (+62.24%).
- NVO annual accounts receivable is now at all-time high.
Performance
NVO Accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly accounts receivable:
$10.08B+$37.41M(+0.37%)Summary
- As of today (May 29, 2025), NVO quarterly accounts receivable is $10.08 billion, with the most recent change of +$37.41 million (+0.37%) on March 31, 2025.
- Over the past year, NVO quarterly accounts receivable has increased by +$1.83 billion (+22.20%).
- NVO quarterly accounts receivable is now at all-time high.
Performance
NVO Quarterly accounts receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Accounts receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
NVO Accounts receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +4.4% | +22.2% |
| 3 y3 years | +62.2% | +85.3% |
| 5 y5 years | +168.8% | +126.7% |
NVO Accounts receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +62.2% | at high | +85.3% |
| 5 y | 5-year | at high | +168.8% | at high | +162.3% |
| alltime | all time | at high | +2085.2% | at high | +2093.3% |
NVO Accounts receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $10.08B(+0.4%) |
| Dec 2024 | $10.04B(+4.4%) | $10.04B(+1.1%) |
| Sep 2024 | - | $9.93B(+8.8%) |
| Jun 2024 | - | $9.12B(+10.7%) |
| Mar 2024 | - | $8.25B(-14.3%) |
| Dec 2023 | $9.62B(+32.1%) | $9.62B(+29.1%) |
| Sep 2023 | - | $7.45B(-16.7%) |
| Jun 2023 | - | $8.94B(+21.0%) |
| Mar 2023 | - | $7.39B(+1.6%) |
| Dec 2022 | $7.28B(+17.6%) | $7.28B(+20.8%) |
| Sep 2022 | - | $6.02B(+5.1%) |
| Jun 2022 | - | $5.73B(+5.4%) |
| Mar 2022 | - | $5.44B(-12.1%) |
| Dec 2021 | $6.19B(+35.0%) | $6.19B(+32.8%) |
| Sep 2021 | - | $4.66B(+11.5%) |
| Jun 2021 | - | $4.18B(-5.5%) |
| Mar 2021 | - | $4.42B(-3.6%) |
| Dec 2020 | $4.58B(+22.7%) | $4.58B(+19.4%) |
| Sep 2020 | - | $3.84B(-0.9%) |
| Jun 2020 | - | $3.87B(-12.8%) |
| Mar 2020 | - | $4.44B(+19.0%) |
| Dec 2019 | $3.73B(+7.0%) | $3.73B(+13.2%) |
| Sep 2019 | - | $3.30B(-6.8%) |
| Jun 2019 | - | $3.54B(+9.7%) |
| Mar 2019 | - | $3.23B(-7.5%) |
| Dec 2018 | $3.49B(+7.4%) | $3.49B(+21.0%) |
| Sep 2018 | - | $2.88B(-2.0%) |
| Jun 2018 | - | $2.94B(+8.9%) |
| Mar 2018 | - | $2.70B(-16.9%) |
| Dec 2017 | $3.25B(+12.9%) | $3.25B(+19.4%) |
| Sep 2017 | - | $2.72B(+1.9%) |
| Jun 2017 | - | $2.67B(+9.3%) |
| Mar 2017 | - | $2.44B(-15.1%) |
| Dec 2016 | $2.88B(+26.9%) | $2.88B(+17.8%) |
| Sep 2016 | - | $2.44B(+3.7%) |
| Jun 2016 | - | $2.36B(-6.1%) |
| Mar 2016 | - | $2.51B(+10.6%) |
| Dec 2015 | $2.27B(+6.5%) | $2.27B(+10.9%) |
| Sep 2015 | - | $2.05B(-4.2%) |
| Jun 2015 | - | $2.14B(+0.6%) |
| Mar 2015 | - | $2.12B(-0.3%) |
| Dec 2014 | $2.13B(+5.5%) | $2.13B(+15.5%) |
| Sep 2014 | - | $1.84B(-12.5%) |
| Jun 2014 | - | $2.11B(+9.2%) |
| Mar 2014 | - | $1.93B(-4.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2013 | $2.02B(+18.2%) | $2.02B(+14.8%) |
| Sep 2013 | - | $1.76B(-8.4%) |
| Jun 2013 | - | $1.92B(+5.7%) |
| Mar 2013 | - | $1.82B(+6.4%) |
| Dec 2012 | $1.71B(+4.9%) | $1.71B(+1.8%) |
| Sep 2012 | - | $1.68B(+1.0%) |
| Jun 2012 | - | $1.66B(-3.1%) |
| Mar 2012 | - | $1.71B(+5.2%) |
| Dec 2011 | $1.63B(+7.4%) | $1.63B(-1.4%) |
| Sep 2011 | - | $1.65B(-9.7%) |
| Jun 2011 | - | $1.83B(+6.0%) |
| Mar 2011 | - | $1.73B(+13.9%) |
| Dec 2010 | $1.52B(+11.6%) | $1.52B(-2.6%) |
| Sep 2010 | - | $1.56B(+9.5%) |
| Jun 2010 | - | $1.42B(-3.8%) |
| Mar 2010 | - | $1.48B(+8.7%) |
| Dec 2009 | $1.36B(+9.8%) | $1.36B(+0.2%) |
| Sep 2009 | - | $1.36B(-0.8%) |
| Jun 2009 | - | $1.37B(+15.2%) |
| Mar 2009 | - | $1.19B(-4.1%) |
| Dec 2008 | $1.24B(+3.7%) | $1.24B(-6.7%) |
| Sep 2008 | - | $1.33B(+0.7%) |
| Jun 2008 | - | $1.32B(+0.9%) |
| Mar 2008 | - | $1.31B(+9.5%) |
| Dec 2007 | $1.19B(+30.6%) | $1.19B(+1.0%) |
| Sep 2007 | - | $1.18B(+7.5%) |
| Jun 2007 | - | $1.10B(+13.3%) |
| Mar 2007 | - | $970.00M(+6.2%) |
| Dec 2006 | $913.47M(+20.4%) | $913.47M(+6.8%) |
| Sep 2006 | - | $855.00M(-1.3%) |
| Jun 2006 | - | $866.27M(+9.2%) |
| Mar 2006 | - | $793.12M(+4.5%) |
| Dec 2005 | $759.00M(+2.0%) | $759.00M(-1.4%) |
| Sep 2005 | - | $769.57M(+1.5%) |
| Jun 2005 | - | $757.91M(+2.4%) |
| Mar 2005 | - | $740.41M(-0.5%) |
| Dec 2004 | $744.27M(+15.2%) | $744.27M(+18.3%) |
| Sep 2004 | - | $629.15M(+0.1%) |
| Jun 2004 | - | $628.31M(+1.6%) |
| Mar 2004 | - | $618.59M(-4.2%) |
| Dec 2003 | $646.02M(+20.4%) | $646.02M(+20.4%) |
| Dec 2002 | $536.54M(+16.8%) | $536.54M(+16.8%) |
| Dec 2001 | $459.38M(-21.7%) | $459.38M(-21.7%) |
| Dec 2000 | $587.05M(-20.7%) | $587.05M(-20.7%) |
| Dec 1999 | $740.38M(-17.2%) | $740.38M(-17.2%) |
| Dec 1998 | $893.87M | $893.87M |
FAQ
- What is Novo Nordisk A/S annual accounts receivable?
- What is the all time high annual accounts receivable for Novo Nordisk A/S?
- What is Novo Nordisk A/S annual accounts receivable year-on-year change?
- What is Novo Nordisk A/S quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Novo Nordisk A/S?
- What is Novo Nordisk A/S quarterly accounts receivable year-on-year change?
What is Novo Nordisk A/S annual accounts receivable?
The current annual accounts receivable of NVO is $10.04B
What is the all time high annual accounts receivable for Novo Nordisk A/S?
Novo Nordisk A/S all-time high annual accounts receivable is $10.04B
What is Novo Nordisk A/S annual accounts receivable year-on-year change?
Over the past year, NVO annual accounts receivable has changed by +$421.58M (+4.38%)
What is Novo Nordisk A/S quarterly accounts receivable?
The current quarterly accounts receivable of NVO is $10.08B
What is the all time high quarterly accounts receivable for Novo Nordisk A/S?
Novo Nordisk A/S all-time high quarterly accounts receivable is $10.08B
What is Novo Nordisk A/S quarterly accounts receivable year-on-year change?
Over the past year, NVO quarterly accounts receivable has changed by +$1.83B (+22.20%)